Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Spectral AI Inc (MDAIW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: MDAIW (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 77.58% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 25444 | Beta 0.42 | 52 Weeks Range 0.08 - 0.90 | Updated Date 04/1/2025 |
52 Weeks Range 0.08 - 0.90 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -51.77% | Operating Margin (TTM) -14.61% |
Management Effectiveness
Return on Assets (TTM) -36.11% | Return on Equity (TTM) -2308.32% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 13981710 |
Shares Outstanding - | Shares Floating 13981710 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Spectral AI Inc
Company Overview
History and Background
Spectral AI Inc. was founded to develop and commercialize its DeepViewu00ae System for rapid and accurate burn wound assessment. The company aims to improve patient outcomes and reduce healthcare costs by providing physicians with objective, real-time information to guide treatment decisions.
Core Business Areas
- Burn Assessment Technology: Spectral AI's core business revolves around developing and marketing its DeepViewu00ae System, a non-contact imaging device that uses spectral analysis to assess burn wound severity and predict healing outcomes.
Leadership and Structure
Spectral AI Inc.'s leadership consists of a management team with expertise in medical device development, regulatory affairs, and commercialization. The company operates with a structure typical of a medical device company, focusing on research and development, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- DeepViewu00ae System: The DeepViewu00ae System is Spectral AI's flagship product. It uses non-contact imaging and AI algorithms to assess burn wound severity and predict healing outcomes. While precise market share data is unavailable, the burn assessment market is fragmented, with competitors offering various methods, including visual assessment, laser Doppler imaging, and other technologies. Competitors include companies specializing in wound care and diagnostic imaging.
Market Dynamics
Industry Overview
The market for burn wound assessment is driven by the need for objective and accurate methods to guide treatment decisions, improve patient outcomes, and reduce healthcare costs. The industry is characterized by ongoing innovation and the adoption of advanced technologies like AI and spectral imaging.
Positioning
Spectral AI aims to position itself as a leader in burn wound assessment with its DeepViewu00ae System, offering a non-contact, objective, and predictive solution. The company's competitive advantage lies in its unique technology and its potential to improve patient outcomes and reduce healthcare costs.
Total Addressable Market (TAM)
The global wound care market, including burn wound care, is estimated to be in the billions of dollars. Spectral AI is positioned to capture a portion of this market with its DeepViewu00ae System. The exact TAM for Spectral AI is dependant on adoption rate of their technology.
Upturn SWOT Analysis
Strengths
- Innovative technology (DeepViewu00ae System)
- Potential to improve patient outcomes
- Non-contact assessment
- AI-powered predictive capabilities
Weaknesses
- Limited commercialization history
- Dependence on a single product
- Requires regulatory approvals
- High upfront costs may limit adoption
Opportunities
- Expanding into other wound care applications
- Partnerships with hospitals and burn centers
- Increasing adoption of AI in healthcare
- Growing awareness of the benefits of objective burn assessment
Threats
- Competition from established wound care companies
- Technological obsolescence
- Regulatory hurdles
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- Smith & Nephew (SNN)
- Integra LifeSciences (IART)
- Mu00f6lnlycke Health Care
Competitive Landscape
Spectral AI's competitive advantage lies in its unique DeepViewu00ae System. However, it faces competition from established wound care companies with broader product portfolios and stronger distribution networks. The non-contact imaging nature of their product is a significant advantage.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company's development stage. Growth is expected to accelerate as the DeepViewu00ae System gains market adoption.
Future Projections: Future growth is dependent on regulatory approvals, commercialization success, and market acceptance of the DeepViewu00ae System. Analyst estimates are based on these factors.
Recent Initiatives: Recent initiatives include securing regulatory approvals, expanding sales and marketing efforts, and developing partnerships with hospitals and burn centers.
Summary
Spectral AI Inc. is a development-stage company with a promising technology for burn wound assessment. The DeepViewu00ae System has the potential to improve patient outcomes and reduce healthcare costs. The company faces challenges in commercialization, competition, and regulatory approvals, but its innovative technology positions it for growth. They need to successfully expand their sales and marketing efforts and obtain reimbursement coverage for their product.
Similar Companies
- SNN
- IART
- BSX
- ABMD
Sources and Disclaimers
Data Sources:
- Company website
- Press releases
- Analyst reports
- Market research reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Spectral AI Inc
Exchange NASDAQ | Headquaters Dallas, TX, United States | ||
IPO Launch date 2021-04-05 | Co-Founder, Chief Innovation Strategist & Senior Advisor to the CEO Mr. Wensheng Fan | ||
Sector Healthcare | Industry Medical Devices | Full time employees - | Website https://www.spectral-ai.com |
Full time employees - | Website https://www.spectral-ai.com | ||
Spectral AI, Inc., an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView System, a predictive analytics platform integrated with the predictive AI-Burn, which combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential and offers clinicians an objective and immediate assessment of a wound's healing potential prior to treatment or other medical intervention; and DeepView SnapShot M, a handheld, portable, and wireless diagnostic tool, that provides a potential enhanced and expanded use for the government and emergency care, first responders, and potentially home health care professionals. The company is headquartered in Dallas, Texas.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.